Group 1 - The core viewpoint of the articles highlights the performance and valuation of Nanwei Medical, which closed at 66.93 yuan with a PE ratio of 22.03 times, significantly lower than the industry average of 49.45 times [1][2] - As of the first quarter of 2025, 17 institutions held shares in Nanwei Medical, with a total holding of 10,647.33 million shares valued at 7.017 billion yuan [1] - The main business of Nanwei Medical includes the research, manufacturing, and sales of minimally invasive medical devices, with key products such as biopsy, hemostasis, and imaging systems [1] Group 2 - In the latest financial report for the first quarter of 2025, Nanwei Medical reported a revenue of 699 million yuan, representing a year-on-year increase of 12.75%, and a net profit of 161 million yuan, also up by 12.18%, with a gross margin of 65.69% [1] - The company ranks 49th in terms of PE ratio within the medical device industry, which has a median PE of 35.92 times [1][2] - The industry average PE ratio is 49.45 times, indicating that Nanwei Medical is undervalued compared to its peers [2]
南微医学收盘上涨2.18%,滚动市盈率22.03倍,总市值125.73亿元